2019年ASCCP基于风险管理共识指南的成本效果分析
该研究利用已发表的宫颈癌自然史与筛查模型,比较2012年与2019年ASCCP异常宫颈癌筛查结果管理指南的终生成本与资源使用。在观察性筛查实践及完美依从场景下,2019指南成本更低且更有效,阴道镜检查和癌症死亡更少,支持「同等风险同等管理」原则。
要点
- 2019指南较2012指南成本更低且更有效。
- 2019指南与更少阴道镜检查和癌症死亡相关。
- 在10万美元/生命年支付阈值下2019指南更具成本效果。
核心结论
- 基于模型的分析提示2019年ASCCP指南总体更有效且更具成本效果,支持「同等风险同等管理」原则。
研究设计与样本
- 利用已发表的宫颈癌自然史与筛查模型,比较2012年与2019年ASCCP管理指南的终生成本和资源使用。
- 评估场景包括观察性筛查实践和完美依从(21岁起3年细胞学,30岁转为3年或5年细胞学联合HPV检测)。
主要发现
- 在观察性筛查实践和完美依从且30岁转为3年联合检测的场景下,2019指南管理筛查测试成本更低且更有效。
- 在21-29岁3年细胞学、30岁转为5年联合检测的场景下,2019指南在10万美元/生命年支付阈值下更具成本效果。
- 所有场景中,2019指南均与更少阴道镜检查和癌症死亡相关。
关键数值与推荐
- 2019指南在10万美元/生命年支付阈值下具有成本效果(针对21-29岁3年细胞学、30岁转为5年联合检测场景)。
临床怎么用
- 临床可依据2019年ASCCP基于风险的指南管理异常宫颈癌筛查结果,以降低成本和资源使用。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The guidelines for managing abnormal cervical cancer screening tests changed from a results-based approach in 2012 to a risk-based approach in 2019. OBJECTIVE: We estimated the cost-effectiveness of the 2019 management guidelines and the changes in resource utilization moving from 2012 to 2019 guidelines. STUDY DESIGN: We utilized a previously published model of cervical cancer natural history and screening to estimate and compare the lifetime costs and the number of screens, colposcopies, precancer treatments, cancer cases, and cancer deaths associated with the 2012 vs 2019 management guidelines. We assessed these guidelines under the scenarios of observed screening practice and perfect screening adherence to 3-year cytology starting at age 21, with a switch to either 3-year or 5-year cytology plus human papillomavirus cotesting at age 30. In addition, we estimated the lifetime costs and life years to determine the cost-effectiveness of shifting to the 2019 management guidelines. RESULTS: Under the assumptions of both observed screening practice and perfect screening adherence with a strategy of 3-year cytology at ages 21 to 29 and switching to 3-year cotesting at age 30, the management of the screening tests according to the 2019 guidelines was less costly and more effective than the 2012 guidelines. For 3-year cytology screening at ages 21 to 29 and switching to 5-year cotesting at age 30, the 2019 guidelines were more cost-effective at a willingness-to-pay threshold of $100,000 per life year gained. Across all scenarios, the 2019 management guidelines were associated with fewer colposcopies and cancer deaths. CONCLUSION: Our model-based analysis suggests that the 2019 guidelines are more effective overall and also more cost-effective than the 2012 guidelines, supporting the principle of "equal management of equal risks."
引用
- Munshi VN, Perkins RB, Sy S, et al. Cost-effectiveness analysis of the 2019 American Society for Colposcopy and Cervical Pathology Risk-Based Management Consensus Guidelines for the management of abnormal cervical cancer screening tests and cancer precursors. Am J Obstet Gynecol. 2021. PMID: 34547295. doi:10.1016/j.ajog.2021.09.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。